AstraZeneca reports another late-stage trial failure within 12 months
Resolves: AstraZeneca announces a second late-stage clinical trial failure (Phase 2/3 or 3) between 2026-07-12 and 2027-06-30.
user-generated· earnings
AstraZeneca reports another late-stage trial failure within 12 months
Market overview
AstraZeneca's recent clinical trial failure for Wainua, despite high expectations, has raised the bar for pipeline success. Historical data shows a near-zero failure rate under CEO Pascal Soriot, making a second late-stage failure unlikely but not impossible. Market reaction suggests credibility is now at risk.
earnings prediction market
- Implied probability (Yes)
- 68%
- Closes
- 2027-06-30
About this prediction
Resolution criteria
AstraZeneca announces a second late-stage clinical trial failure (Phase 2/3 or 3) between 2026-07-12 and 2027-06-30.
Source: user-generated
More earnings markets
- Will cash burn exceed $5M in Q4? — 65% Yes
- Will Venyra beat Q4 2026 revenue consensus of $230M? — 85% Yes
- Will Nuburu secure emergency financing by Q3 end? — 35% Yes
- Will Everpure, Inc. report a non-GAAP EPS beat for the quarter ended June 30, 2026? — 50% Yes
- Will KR miss Q4 operating margin guidance? — 65% Yes
- Will George Risk report Q4 2026 revenue above $13M? — 85% Yes
- Will DCI beat Q4 EPS consensus of $0.88? — 65% Yes
- Will inventory days decrease below 70 by year-end? — 40% Yes
No one's made a Conviction call on this yet. Be the first to call it →
Loading…